Extrovis AG is a global Contract Research, Development & Manufacturing Organization (CRDMO) that develops and manufactures complex specialty therapeutics, including sterile antibiotics, oncology and cytotoxic formulations, and female hormone products. The company provides R&D, regulated-market manufacturing (USFDA, EU‑GMP) and supply‑chain and regulatory support across drug substances and finished dosage forms.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentChemical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Sterile cephalosporins, highly potent monobactams, advanced intermediates and controlled substances; with aseptic processing, containment, scale-up, purification and cGMP-compliant production.
Pharmaceutical manufacturing
Oncology solid dosage forms, injectables, topicals and oral liquids as well as cephalosporins, female hormones and general topicals; with development, tech transfer, scale-up, fill-finish, packaging and commercial supply.
Research and Development
Development of new and differentiated FDFs, APIs and intermediates; in addition, drug-device combinations, advanced delivery systems, peptides and sterile injectables.
CDMO partnership and tech transfer
Long-term development and manufacturing partnerships with tech transfer, scale-up, commercial supply, lifecycle management and support for regulated markets.
Knowledge
No knowledge articles yet
Once Extrovis AG has claimed this profile, we'll publish editorial articles and case studies here together.